Keywords: BNab; broadly neutralising antibody; CTL; cytotoxic lymphocyte; DAA; direct-acting antiviral; HBV; hepatitis B virus; HCV; hepatitis C virus; HIV; human immunodeficiency virus; NGS; next generation sequencing; SGA; single genome amplification; SNP; single
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Influenza; Monoclonal antibody; Immunization; Pandemic; Vaccine; Prophylaxis; bNAb; broadly neutralizing antibody; GAP; Global Action Plan for influenza vaccines; mAb; monoclonal antibody; ICTRP; International Clinical Trials Registry Platform;
Keywords: Ag; antigen; bnAb; broadly neutralizing anti-HIV Ig; CLL; chronic lymphocytic leukemia; EBV; Epstein Barr virus; GBM; glomerular basement membrane; GN; glomerulonephritis; GP; Goodpasture; GPS; GP syndrome; HC; heavy chain; HCDR3; heavy chain complementar
Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds
Keywords: MPER; membrane-proximal external region; TMD; transmembrane domain; Env; HIV-1 envelope glycoprotein; MD; molecular dynamics; bNAb; broadly neutralizing antibody; CDR-H3; complementarity-determining region three of the heavy chain; HC; heavy chain; WT; wi
Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges
Keywords: Human immunodeficiency virus; 3BNC117; Broadly neutralizing antibody; Viremia; Anti-HIV immune response; Immunotherapy; HIV-1; human immunodeficiency virus type-1; SHIV; simian-human immunodeficiency virus; AIDS; acquired immune deficiency syndrome; bNAb;
Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region
Keywords: MPER; membrane proximal external region; FP; fusion peptide; bnAb; broadly neutralizing antibody; HIV-1; DNA vaccine; gp41; Membrane-proximal external region; Broadly neutralizing antibodies;
Functional Contacts between MPER and the Anti-HIV-1 Broadly Neutralizing Antibody 4E10 Extend into the Core of the Membrane
Keywords: MPER; membrane-proximal external region; bNAb; broadly neutralizing antibody; CDRH3; complementarity-determining region three of the heavy chain; TMD; transmembrane domain; VL; virus-like; WT; wild-type; PsV; pseudovirus particle; NBD; 4-chloro-7-nitroben
Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody
Keywords: gp120; glycoprotein 120 from HIV-1; rgp120; recombinant gp120; V1,V2,V3; the first second and third variable regions of gp120; C1,C2,C3; the first second and third constant regions of gp120; bN-mAb; broadly neutralizing monoclonal antibody; bNAb; broadly
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
Keywords: ADCC; Antibody-dependent cell-mediated cytotoxicity; ARV; Anti-retroviral; AZT; Zidovudine; bnAb; Broadly neutralizing antibody; CD4bs; CD4 binding site; dIgA; Dimeric IgA; FcRn; Neonatal Fc receptor; GalCer; Galactosyl ceramide; GI; Gastrointestinal; GU;
Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display
Keywords: DENV; Dengue virus; DHF; Dengue hemorrhagic fever; DSS; Dengue shock syndrome; ADE; antibody dependent enhancement of infection; bNAb; broadly neutralizing antibody; DIII; domain III; DI; domain I; DII; domain II; mAb; monoclonal antibody; IgH; immunoglob
Progress in HIV-1 vaccine development
Keywords: HIV-1; vaccine; T cells; B cells; broadly neutralizing antibodies; ADCC; Antibody-dependent cellular cytotoxicity; BCR; B-cell antigen receptor; bnAb; Broad neutralizing antibody; Env; Envelope; gp; Glycoprotein; HC; Heavy chain; HCDR3; Immunoglobulin thi
Immunogen design for HIV-1 and influenza
Keywords: HIV-1; human immunodeficiency virus-1; Env; envelope; PNGS; potential N-linked glycosylation sites; bNAb; broadly neutralizing antibody; GL; germline; T/F; Transmitted/Founder virus; MPER; membrane proximal external region; OD; Outer domain; CD4bs; CD4 bi